Precipio (NASDAQ:PRPO) Releases Quarterly Earnings Results

Precipio (NASDAQ:PRPO) released its quarterly earnings data on Friday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $7.02 million for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.

Precipio Stock Performance

Shares of Precipio stock traded up $0.29 during trading on Friday, reaching $23.50. The company’s stock had a trading volume of 75,806 shares, compared to its average volume of 42,911. The company has a 50-day moving average price of $23.42 and a two-hundred day moving average price of $25.03. Precipio has a fifty-two week low of $13.80 and a fifty-two week high of $33.63. The firm has a market cap of $42.06 million, a PE ratio of -50.00 and a beta of 1.30. The company has a current ratio of 1.56, a quick ratio of 1.33 and a debt-to-equity ratio of 0.05.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PRPO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a report on Friday, July 17th. Wall Street Zen cut shares of Precipio from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Precipio has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Susquehanna International Group LLP acquired a new stake in shares of Precipio during the third quarter worth about $194,000. Geode Capital Management LLC raised its stake in Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 789 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after acquiring an additional 1,400 shares during the last quarter. 10.45% of the stock is owned by hedge funds and other institutional investors.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.